Patients & family
Glycostem Therapeutics is focused on developing innovative off-the-shelf cell therapies for cancer patients. Our therapies are based on allogeneic Natural Killer (NK) cells and our lead product is oNKord®. oNKord® is an off-the-shelf NK cell cancer therapy under development. A phase I/IIa study clinical trial in patients with Acute Myeloid Leukemia is now ongoing to evaluate the safety and efficacy of oNKord®.
Patients and families that are interested and would like to receive information about the clinical trial, visit the clinical trial page or contact us.
To view the pages in other languages, please select through the language button.
Clinical trial in patients with Acute Myeloid Leukemia
oNKord® is a frozen off-the-shelf investigational cell therapy product for venous infusion which contain a large number of NK cells. oNKord® is expanded and activated ex vivo, currently in development for the treatment of hematologic malignancies and solid tumors.
oNKord® is available only for patients enrolled in clinical trials. A phase I/IIa study of oNKord® for the treatment of acute myeloid leukemia was initiated in November 2020. More details about the clinical trial are publicly available through ClinicalTrials.gov.
Earlier trial result
A phase I clinical study of oNKord® was completed in the Netherlands in 2015. It demonstrated a good safety profile for single infusion and promising efficacy signal in 10 elderly and frail patients with acute myeloid leukemia (AML) not eligible for hematopoietic stem cell transplantation.
About NK cell therapy
NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells.
NK cells play an important role in control and even cure of both solid and hematological malignancies, like Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM).
Better immune system response
When the cells of a patient’s immune system are not strong enough to fight cancer cells, the infusion of NK cells collected from a donor may contribute to a better response by the patient's immune system. Thus, venous infusion of a large number of NK cells could contribute to the body's fight against cancer cells.
Glycostem Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer.
Glycostem’s commitment to the patient community is not limited to NK cell therapies development, but encompasses a better understanding of the needs and experiences of patients with cancer and their families.
Our lead product
oNKord® is our lead investigational product and is produced in our state-of-the art closed manufacturing facilities, located in Oss, the Netherlands. Glycostem’s manufacturing facilities have been granted license to produce NK cells for clinical trials by the competent authority in the Netherlands.
Our highly qualified staff ensures our solutions meet the highest scientific, operational and quality standards possible. They collaborate every day towards the shared ambition of curing cancer.
Leveraging the experiences and information gained from oNKord® , Glycostem is furthermore developing a range of CAR-NK and TCR-NK products as our second and third generation products.
Chimeric Antigen Receptor (CAR)-engineered NK cells are today one of the most attractive and innovative preclinical candidates in cellular immunotherapy, because of their dedicated functionality, tumor targeting, prolonged persistence and fewer side effects compared to current CAR-T treatments. As a next step, we are focusing on the development of our unique CAR-NK products, and preparing for preclinical testing. We expect to initiate phase I trials by early 2022. For a third-generation product, Glycostem is working on TCR-NK products which may be around one year after the phase I CAR-NK trial.
For information about our investigational therapies, please view our pipeline.
A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production. We build bridges between the commercial and scientific parts of our companies and maintain close relationships with our partners.